Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.49 |
| ▸ | TSHR | P16473 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6887603 | 0.90 | MAPT (0.58) | TDP1ALDH1A1L3MBTL1TSHRMAPT | |
| SCHEMBL7713695 | 0.87 | TDP1 (0.64) | TDP1ALDH1A1L3MBTL1MAPK1TSHR | |
| SCHEMBL29369910 | 0.84 | TDP1 (0.74) | TDP1ALDH1A1L3MBTL1MAPK1TSHR | |
| SCHEMBL1694924 | 0.84 | TDP1 (0.74) | TDP1ALDH1A1L3MBTL1MAPK1TSHR | |
| SCHEMBL6882413 | 0.84 | SMN1; SMN2 (0.48) | TDP1ALDH1A1L3MBTL1MAPK1TSHR | |
| SCHEMBL27374559 | 0.80 | TDP1 (0.71) | TDP1ALDH1A1L3MBTL1MAPK1TSHR | |
| SCHEMBL7713706 | 0.79 | MAPT (0.64) | TDP1ALDH1A1L3MBTL1TSHRMAPT | |
| SCHEMBL28252189 | 0.77 | MAPT (0.63) | TDP1ALDH1A1L3MBTL1TSHRMAPT | |
| SCHEMBL11269737 | 0.76 | TDP1 (0.62) | TDP1ALDH1A1L3MBTL1MAPK1TSHR | |
| SCHEMBL1090743 | 0.76 | MAPT (0.74) | TDP1ALDH1A1L3MBTL1TSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040254182-A1 | Enhanced propertied pharmaceuticals | ROHM AND HAAS COMPANY | 2004-12-16 | — | — | US | disclosed |
| EP-1272463-A1 | ENHANCED PROPERTIED PHARMACEUTICALS | ROHM AND HAAS COMPANY (US) | 2003-01-08 | — | — | EP | disclosed |
| WO-2002072559-A1 | PROCESS TO INTERMEDIATES FOR BIOLOGICALLY ACTIVE COMPOUNDS | ROHM AND HAAS COMPANY (US) | 2002-09-19 | — | — | WO | disclosed |
| US-20010039343-A1 | Process to intermediates for biologically active compounds | MULVIHILL MARK JOSEPH (US) | 2001-11-08 | — | — | US | disclosed |
| WO-2001056358-A2 | ENHANCED PROPERTIED PESTICIDES | ROHM AND HAAS COMPANY (US) | 2001-08-09 | — | — | WO | disclosed |
| WO-2001054481-A2 | ENHANCED PROPERTIED PHARMACEUTICALS | ROHM AND HAAS COMPANY (US) | 2001-08-02 | — | — | WO | disclosed |
| WO-2001055082-A2 | INTERMEDIATES FOR BIOLOGICALLY ACTIVE COMPOUNDS | ROHM AND HAAS COMPANY (US) | 2001-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254182-A1 | Enhanced propertied pharmaceuticals | ABCB1, ABCB11, ABCG2 | TDP1 4438/4885ALDH1A1 118/4885L3MBTL1 4527/4885 |
| US-20010039343-A1 | Process to intermediates for biologically active compounds | DDT, CYP4X1, CYP1B1 | TDP1 1254/4885ALDH1A1 164/4885L3MBTL1 2677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.